News Article | November 23, 2016
According to Stratistics MRC, the Global Biopreservation Market is accounted for $2.17 billion in 2015 and is expected to reach $4.75 billion by 2022 growing at a CAGR of 11.84% during the forecast period. Rising healthcare costs, improved research and development in the field and rising usage of regenerative medicine are some of the factors boosting the market growth. However, huge cost of advanced techniques is one of the key factors hampering the market. By cell provider’s volume, Tumor cells segment dominated the global market with largest share in 2014 due to several applications in research & development. By geography, North America dominated the global market with more than 40% of the share in 2014 owing to therapies in biomedical research and rise in the population requiring diagnosis in this region. However, the Asia-Pacific market is anticipated to grow at the fastest CAGR during the forecast period. Some of the key players in Biopreservation market include Qiagen N.V., Biolife Solutions, Inc., Lifeline Scientific, Inc., Biomatrica, Inc., Taylor-Wharton Cryogenics LLC, Custom Biogenic Systems, Inc., BioCision, LLC, Sigma-Aldrich Corporation, Cesca Therapeutics Inc., Atlanta Biologicals Inc, Princeton CryoTech Inc., VWR Corporation, Core Dynamics Ltd, So-Low Environmental Equipment Co., Inc., LABVANTAGE Solutions, Inc., Biogenics, Thermo Fisher Scientific and Panasonic Corporation. Applications Covered: • Bio-banking o Human sperms o Human eggs o Veterinary IVF • Regenerative Medicine o Gene therapy o Cell therapy o Other Regenerative Medicines • Drug Discovery • Other Applications Biospecimens Covered: • Stem Cells • Human Tissue Samples • Organs • Other Biospecimens Products Covered: • Media o Nutrient Media o Pre-formulated o Growth Factors and Supplements o Home-brew o Sera • Laboratory Information Management System (LIMS) • Equipment o Incubators o Consumables o Centrifuges o Temperature Control Systems o Accessories o Liquid Nitrogen (LN2) Tanks o Other Equipments Cell Providers Volumes Covered: • Mesenchymal Stem Cells (MSC) • CD34+ cells • Tumor cells • Induced Pluripotent Stem Cells (iPSC) • CD19+ cells • Human Embryonic Stem Cells (hESC) • Other Cell Providers Volumes End Users Covered: • Hospitals • Biobanks • Gene Banks • Other End Users Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements
News Article | November 16, 2016
— Rising healthcare costs, improved research and development in the field and rising usage of regenerative medicine are some of the factors boosting the market growth. However, huge cost of advanced techniques is one of the key factors hampering the market. By cell provider’s volume, Tumor cells segment dominated the global market with largest share in 2014 due to several applications in research & development. By geography, North America dominated the global market with more than 40% of the share in 2014 owing to therapies in biomedical research and rise in the population requiring diagnosis in this region. However, the Asia-Pacific market is anticipated to grow at the fastest CAGR during the forecast period. Some of the key players in Biopreservation market include Qiagen N.V., Biolife Solutions, Inc., Lifeline Scientific, Inc., Biomatrica, Inc., Taylor-Wharton Cryogenics LLC, Custom Biogenic Systems, Inc., BioCision, LLC, Sigma-Aldrich Corporation, Cesca Therapeutics Inc., Atlanta Biologicals Inc, Princeton CryoTech Inc., VWR Corporation, Core Dynamics Ltd, So-Low Environmental Equipment Co., Inc., LABVANTAGE Solutions, Inc., Biogenics, Thermo Fisher Scientific and Panasonic Corporation. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/
News Article | November 9, 2016
BERLIN, Germany, Nov. 09, 2016 (GLOBE NEWSWIRE) -- InterDigital (NASDAQ:IDCC), Fraunhofer Heinrich Hertz Institute HHI, and Core Network Dynamics (CND), three partners from the H2020 5GPPP 5G-Crosshaul consortium, today announced the successful result of an extended, real-world deployment of an integrated fronthaul/backhaul network delivering 5G throughput and latency. The test, a first of its kind, sets the stage for cost-effective, highly flexible 5G network architecture. The results of the integrated millimeter wave (mmW) fronthaul/backhaul 5G Berlin Testbed were announced at the November 2nd IEEE 5G Berlin Summit and will be further presented at the 5G-PPP Global 5G event, taking place today and tomorrow in Rome. The 5G-Crosshaul test was carried out over more than a month at the Fraunhofer Heinrich Hertz Institute in Berlin, and delivered higher than 1.2 Gbps throughput and less than millisecond latency. Beyond the speed, the test’s integrated fronthaul/backhaul provides a working model for future 5G networks that will combine 4G architecture with a 5G fronthaul-based network edge. With this deployment, 5G radio network solutions can be implemented using commodity servers or even in the cloud – a major innovation that throws open the doors for new operator models. The 5G Berlin Testbed is a 5G field trial of InterDigital’s EdgeLink™ 60GHz solution, multiplexing both backhaul and CND’s Cloud-RAN next generation fronthaul solution over an integrated mmW mesh transport network. The system is installed outdoors, executing under environmental conditions from the end of September through November. The trial has included both natural and induced link failure events, to test network resiliency. “Millimeter wave technology will be a decisive cornerstone to bring 5G forward to enhanced mobile broadband harvesting new spectrum opportunities well above 6GHz, ultra-dense deployments and energy-efficient multi-Gigabit transmission,” explains Dr. Thomas Haustein, Head of Department for Wireless Communication and Networks at Fraunhofer HHI. “The 5G Berlin Testbed will provide valuable information that can be used to help advance the evolving 5G standards and specifications. We are already adapting OpenEPC to support critical 5G requirements. These include a distributed core network, plus architectures to support C-RAN and the cloudification of the radio access network,” said Carsten Brinkschulte, CEO, Core Network Dynamics. “Many companies have demonstrated systems that they qualify as ‘5G’ because of speed or latency characteristics, but this extended outdoor trial is the first example of a network edge architecture, tested in real-world conditions, that will be a key in eventual 5G deployment,” said, Alan Carlton, Vice President, InterDigital Europe. “Crosshaul’s major innovation may set the stage for a world where our definitions of what constitutes a network operator or infrastructure equipment are radically changed.” 5G-Crosshaul is an international project with 21 members aimed at developing integrated fronthaul and backhaul system solutions to support flexibility and unified management for 5G network architectures. To learn more about the project, visit http://5g-crosshaul.eu/. InterDigital develops mobile technologies that are at the core of devices, networks, and services worldwide. We solve many of the industry's most critical and complex technical challenges, inventing solutions for more efficient broadband networks and a richer multimedia experience years ahead of market deployment. InterDigital has licenses and strategic relationships with many of the world's leading wireless companies. Founded in 1972, InterDigital is listed on NASDAQ and is included in the S&P MidCap 400® index. InterDigital is a registered trademark of InterDigital, Inc. EdgeLink is a trademark of InterDigital, Inc. Innovations for the digital society of the future are the focus of research and development work at the Fraunhofer Heinrich Hertz Institute HHI. In this area, Fraunhofer HHI is a world leader in the development for mobile and optical communication networks and systems as well as processing and coding of video signals. Together with international partners from research and industry, Fraunhofer HHI works in the whole spectrum of digital infrastructure – from fundamental research to the development of prototypes and solutions. www.hhi.fraunhofer.de About Core Network Dynamics Headquartered in Berlin, Core Network Dynamics develops and markets OpenEPC, a complete mobile network infrastructure in software. Target markets include: carriers designing next-generation mobile networks using SDN/NFV; first responder/public safety organizations requiring a secure private LTE network compatible with off-the-shelf Smartphones; companies operating in remote areas where mobile coverage is patchy or non-existent; and operators evaluating advanced Mobile Edge Computing (MEC) concepts to implement distributed mobile networks for IoT applications. www.corenetdynamics.com
Maffei S.,University of Milan |
Pennarossa G.,University of Sassari |
Brevini T.A.L.,University of Milan |
Arav A.,Core Dynamics |
Gandolfi F.,University of Milan
Human Reproduction | Year: 2014
STUDY QUESTION: Does directional freezing improve the structural and functional integrity of ovarian fragments compared with conventional slow freezing and to whole ovary cryopreservation? SUMMARY ANSWER: Compared with slow freezing, the use of directional freezing significantly improves all structural and functional parameters of ovarian fragments assessed in vitro and, overall, whole ovaries were better preserved than ovarian fragments. WHAT IS KNOWN ALREADY: Directional freezing has been developed to provide an alternative way to cryopreserve large biological samples and it is known to improve the structural and functional integrity of whole ovaries. Conventional slow freezing of ovarian fragments is the procedure more widely used in clinical settings but it causes substantial structural damage that limits the functional period after transfer back into the patient. STUDY DESIGN, SIZE, DURATION: We performed a 2 × 2 factorial design experiment on a total of 40 sheep ovaries, divided into four groups (n = 10 ovaries per group): (i) directional freezing of whole ovary (DFwo); (ii) directional freezing of ovarian fragments (DFof); (iii) conventional freezing of whole ovary (CFwo); (iv) conventional freezing of ovarian fragments (CFof). An additional eight ovaries were used as fresh controls. PARTICIPANTS/ MATERIALS, SETTING, METHODS: Ewe ovaries were randomly assigned to one of the experimental groups and frozen accordingly. Upon thawing, ovarian tissue was examined morphologically and cultured in vitro for 7 days. Samples were analyzed for cell proliferation and apoptosis, for DNA damage and repair activity, and for the presence of a panel of heat shock proteins (HSPs) by immunohistochemistry. MAIN RESULTS AND THE ROLE OF CHANCE: Most studied parameters were significantly improved (P < 0.05) in all samples cryopreserved with directional compared with slow freezing. The proportion of primordial follicles, which developed to the primary stage in whole ovaries (53 ± 1.7%) and in ovarian fragments (44 ± 1.8%) cryopreserved with directional freezing, was greater than with slow frozen whole ovaries (6 ± 0.5%, P = 0.001) or fragments (32 ± 1.5%, P = 0.004). After 7 days of culture, cell proliferation in DFwo (28 ± 0.73%) was the highest of all groups (P < 0.05) followed by DFof (23 ± 0.81%), CFof (20 ± 0.79%) and CFwo (9 ± 0.85%). Directional freezing also resulted in a better preservation of the cell capacity to repair DNA damage compared with slow freezing both in whole ovaries and ovarian fragments. Apoptosis and HSP protein levels were significantly increased only in the CFwo group. Direct comparison demonstrated that, overall, DFwo had better parameters than DFof and was no different from the fresh controls. LIMITATIONS, REASONS FOR CAUTION: The study is limited to an in vitro evaluation and uses sheep ovaries, which are smaller than human ovaries and therefore may withstand the procedures better. WIDER IMPLICATIONS OF THE FINDINGS: Improved integrity of ovarian morphology may translate to improved outcomes after transplantation. Alternatively, the particularly good preservation of whole ovaries suggests they could provide a source of ovarian follicles for in vitro culture in those cases when the presence of malignant cells poses a substantial risk for the patient. STUDY FUNDING/COMPETING INTEREST(S): Supported by: Associazione Italiana per la Ricerca sul Cancro (AIRC) IG 10376, Carraresi Foundation and by Legge 7 Regione Autonoma Sardegna (R.A.S). There are no conflicts of interest. © The Author 2013.
Farinelli S.,Core Dynamics
Journal of Geometric Mechanics | Year: 2015
We have embedded the classical theory of stochastic finance into a differential geometric framework called Geometric Arbitrage Theory and show that it is possible to: Write arbitrage as curvature of a principal fibre bundle. Parameterize arbitrage strategies by its holonomy. Give the Fundamental Theorem of Asset Pricing a differential homotopic characterization. Characterize Geometric Arbitrage Theory by five principles and show they are consistent with the classical theory of stochastic finance. Derive for a closed market the equilibrium solution for market portfolio and dynamics in the cases where: Arbitrage is allowed but minimized. - Arbitrage is not allowed. Prove that the no-free-lunch-with-vanishing-risk condition implies the zero curvature condition. The converse is in general not true and additionally requires the Novikov condition for the instantaneous Sharpe Ratio to be satisfied. © American Institute of Mathematical Sciences.
Core Dynamics | Date: 2010-04-09
Provided is a method for the sterilization of a biological preparation including desired viable biological entities. The method includes irradiating a dried (e.g. freeze-dried) biological preparation with UV radiation at an intensity and for a duration sufficient to reduce the amount or activity of living-matter contaminants in the biological preparation, the intensity and duration selected such that at least part of the desired biological entities in the sample remains viable. The described method is particularly suitable for the reduction of the amount or activity of contaminants such as bacteria or viruses from biological preparations including red blood cells or platelets.
Core Dynamics | Date: 2011-12-21
Provided is a method of designing a system for use in a process for freezing a biological material at a desired cooling rate, the system including a device for freezing biological material including a cooling unit and a heat insulation unit, and a container configured for receiving therein the biological material; the method including: designing the container to have a first portion and a second portion; designing the heat insulation unit to have a first receiving portion and a second receiving portion; configuring the first and second portions of the heat insulation unit to receive therein the first and second portions of the container, respectively, to ensure that the second portion of the container is in thermal contact with the cooling unit; determining dimensions of the first and second portions of the container and of the heat insulation unit in accordance with the desired cooling rate.
Core Dynamics | Date: 2011-03-29
Provided is a preservation solution for preserving biological material at low temperature including one or more polyphenols and a method for preservation of biological material, the method includes adding the preservation solution to biological material, cooling the biological material and storing it under appropriate storing conditions. The present method may be used for hypothermic preservation or for cryopreservation, including freezing and lyophilization, and may be used with any biological material, including cells selected from RBC, WBC, MNC, UCB MNC and bacteria. In the case of RBC, also disclosed is a method for its freezing such that upon thawing, the material has less than 2% free hemoglobin.
Core Dynamics | Date: 2011-01-06
The claimed subject matter is based on the finding that it is possible to cryopreserve cancellous bone tissue with viable cells (after reconstitution by either thawing or rehydration), the viability after reconstitution being comparable to that of a fresh sample (without freezing) and of beneficial value for use in, for example, transplantation. Thus, provided is a method for cryopreserving a cancellous bone sample. The cryopreserved cancellous bone sample can be in dry form, for example, lyophilized. Also provided is a cryopreserved, in dry form, bone sample and the use of a cryopreserved bone sample; a method for identifying such cryopreserved cancellous bone tissue and uses thereof.